RTOG 0974 OR NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ (DCIS) Resected by Lumpectomy
Description of Research
The purpose of this study is to compare the effects, good and/or bad, of radiation therapy with or without the addition of trastuzumab to find out which treatment is better. The drug trastuzumab is called a targeted therapy because it targets breast cancers that make too much of a protein called HER2. These cancers are called HER2-positive. Trastuzumab is approved by the FDA for the treatment of invasive HER2-positive breast cancer. Trastuzumab has not been approved as a treatment for DCIS breast cancer and is considered investigational in this study.
Jedidiah Monson, M.D.
DCIS Resected by Lumpectomy, determined to be HER2- Positive by Central Testing.